[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Ishikawa S, Koyama T, Kumagai A, Takeuchi I, Ogawa D: [A case of small cell carcinoma of the ureter with SIADH-like symptoms]. Nihon Hinyokika Gakkai Zasshi; 2004 Jul;95(5):725-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell carcinoma of the ureter with SIADH-like symptoms].
  • Primary small cell carcinoma of the ureter is very rare.
  • Computed tomography revealed left hydronephrosis, a peri-ureteral left lower quadrant mass, and retroperitoneal (RP) lymphadenopathy.
  • Urography showed an obstructing mass invading the left ureter.
  • Comprehensive metastatic evaluation revealed no other lesions.
  • Thus, we diagnosed primary small cell carcinoma of the ureter with RP lymph node metastases.
  • In addition, he developed SIADH-like symptoms, and we strongly suspected that it was due to ectopic production of ADH from this carcinoma.
  • He was treated with systemic chemotherapy (methotrexate, epirubicin, and cisplatin).
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354720.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR: Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer; 2002 Feb 1;86(3):326-30
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer.
  • Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m(-2) and cisplatin 75 mg m(-2) on day 1 and repeated every 21 days, to a maximum of six cycles.
  • The median delivered dose-intensity was 98% (range 79-102%) of the planned dose for both drugs.
  • The median time to progression was 6.9 months, and the median overall survival was 10.4 months.
  • There was one toxic death in a patient with grade 4 granulocytopenia who developed acute abdomen.
  • Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer, and warrants further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paclitaxel / analogs & derivatives. Taxoids. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Treatment Outcome. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urothelium

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 The Cancer Research Campaign
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2546-52 [10561321.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1385-8 [10631471.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1461-5 [10643537.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):840-6 [10673526.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1058-61 [10694557.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):74-9 [10741298.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2537-44 [10893284.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3247-55 [10986057.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1612-6 [11104554.001]
  • [Cites] J Urol. 2001 Jan;165(1):67-71 [11125366.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2527-33 [11331332.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1078-9 [8683639.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1655-9 [8932351.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):255-60 [9440750.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1844-8 [9586899.001]
  • [Cites] Urology. 1998 Jul;52(1):56-60 [9671871.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):370-4 [9703285.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2722-7 [9704723.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3392-7 [9779718.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1342-5 [9823976.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • (PMID = 11875692.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2375206
  •  go-up   go-down


3. Hisamatsu H, Yamashita S: [A case of metastatic lung cancer with cavitation due to urothelial carcinoma]. Hinyokika Kiyo; 2010 May;56(5):269-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic lung cancer with cavitation due to urothelial carcinoma].
  • We report a rare case of lung cancer with cavitation that was caused by metastasis of urothelial carcinoma.
  • Computed tomography revealed a left ureter tumor, which was removed by left nephroureterectomy in October 2003.
  • However, a part of the ureter could not be resected because of the adhesion that had occurred after a previous operation.
  • The patient was diagnosed with sigmoid colon cancer, and she underwent sigmoidectomy and resection of the remaining part of the ureter in August 2004.
  • Subsequently, transurethral resection was performed several times for bladder tumor.
  • The pathological diagnosis in February 2005 was pT2.
  • Cisplatin-based intra-arterial chemotherapy was performed because it was not possible to perform a cystectomy due to the poor performance status.
  • In March 2006, computed tomography of the chest revealed a mass shadow with a cavity in the left lower lung field.
  • This was diagnosed as primary or metastatic lung cancer and was treated by left lower lobectomy in November 2006.
  • On the basis of the pathological findings, we diagnosed the mass as metastatic tumor secondary to the urothelial carcinoma.
  • Despite general chemotherapy, the patient's condition deteriorated, and the patient died 1 year later.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Ureteral Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Female. Humans. Nephrectomy. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed. Ureter / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519925.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Segawa N, Hamada S, Takahara K, Tanaka K, Daimon M, Kanehara H, Suzuki T, Iwamoto Y, Tsuji M, Azuma H, Okuda J, Katsumata T, Katsuoka Y: [Ureteral-abdominal aortic fistula during the exchange of ureteral stenting: a case report]. Hinyokika Kiyo; 2007 Aug;53(8):565-9
MedlinePlus Health Information. consumer health - Ureteral Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a patient with a fistula between the left ureter and abdominal aorta.
  • The patient was a 44-year-old male who had undergone radiation therapy (intraoperative: 25 Gy, external beam: 50 Gy) and chemotherapy (CDDP: 250 mg) for retroperitoneal lymph node metastasis from seminoma.
  • Massive hemorrhage was suspected to have prompt fistula formation between the left ureter and the aorta.
  • In addition, the left ureter was ligated proximal to the fistula and percutaneous left nephrostomy were performed.
  • We should be aware that uretero-arterial fistula can occur as a serious complication of ureteral catheter exchange after prolonged ureteral stenting and radiation therapy.
  • [MeSH-minor] Adult. Aorta, Abdominal. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / radiotherapy. Male. Retroperitoneal Space. Seminoma / pathology. Seminoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874549.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Segawa N, Azuma H, Takahara K, Hamada S, Kotake Y, Tsuji M, Katsuokai Y: [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report]. Hinyokika Kiyo; 2008 Jan;54(1):13-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report].
  • We report a case of port-site metastasis of bladder cancer after left retroperitoneoscopy-assisted nephroureterectomy and cystectomy.
  • The diagnosis was invasive bladder cancer with bone metastasis.
  • He received two courses of chemotherapy (methotrexate, vinblastine, adriamycin, cisplatin), and this resulted in resolution of the bone metastases.
  • Two months later, abdominal and pelvic computed tomography showed a bladder tumor invading the left lower ureter with hydronephrosis.
  • The patient was unable to undergo systemic chemotherapy because of renal dysfunction.
  • Four months later, a lateral abdominal wall tumor was found at a port-site, and needle biopsy confirmed this to be metastatic urothelial carcinoma.
  • Clinicians need to be aware of port-site metastasis, particularly in patients with UC, and take steps to prevent it during laparoscopic procedures.
  • [MeSH-major] Abdominal Neoplasms / secondary. Carcinoma / surgery. Cystectomy. Endoscopy. Neoplasm Invasiveness. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260354.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int; 2006 Dec;98(6):1176-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
  • PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data.
  • Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02).
  • On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS.
  • In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence.
  • The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS.
  • CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed.
  • Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol.
  • Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / surgery. Neoplasm Staging / methods. Prognosis. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Apr;51(4):1141-2 [17415912.001]
  • (PMID = 17125474.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846; United States / NCI NIH HHS / CA / T32 CA079449-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Chen ZF, Zheng SB, Wu P, Zhang P, Jiang YD, Zhao SC, Mao XM, Chen ZR, Shan ZF: [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec;30(12):2765-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature].
  • OBJECTIVE: To study the clinicopathological characteristics of synchronous squamous cell carcinoma (SCC) of the renal pelvis and SCC of the ureter.
  • METHODS: The clinical data of two cases of synchronous SCC of the renal pelvis and SCC of the ureter were retrospectively reviewed and analyzed.
  • In case 1, a 68-year-old man with hematuria for a month, imaging modalities revealed a right renal pelvis tumor and a right distal ureter tumor.
  • Case 2, a 60-year-old man with the complaint of lower abdominal pain and left flank pain for a month, was diagnosed as left distal ureteral stone in another hospital.
  • Ureterolithotomy was performed and a ureteral tumor was found at the lower site of the stone intraoperatively.
  • The pathological report demonstrated SCC, and the patient was transferred to our hospital for further treatment.
  • Neither of patients received adjuvant radiotherapy/chemotherapy.
  • RESULTS: Moderately differentiated SCC was reported in both of renal pelvis and ureter in case 1 and the tumor invaded the subepithelial connective tissue in the renal pelvis and superficial muscle in the ureter.
  • In case 2, moderately differentiated SCC of the left renal pelvis with colon metastasis and poorly differentiated SCC of the ureter was reported with two retroperitoneal lymph node metastases.
  • The two patients died from tumor recurrence and metastasis 5 and 6 months after the surgery, respectively.
  • CONCLUSION: Synchronous SCC of the renal pelvis and SCC of the ureter are rare and has high likeliness of early recurrence and metastasis, often with poor prognosis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21177201.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


8. Helke C, May M, Hoschke B: [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function]. Aktuelle Urol; 2006 Sep;37(5):363-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
  • [Transliterated title] Gemcitabine/Carboplatin-Chemotherapie in der Behandlung des metastasierten Urothelkarzinoms unter besonderer Berücksichtigung von Patienten mit eingeschränkter Nierenfunktion.
  • PATIENTS AND METHODS: 30 consecutive patients with metastatic TCC [mean age: 68 (range: 47 - 82) years, median ECOG-PS:1] were treated with gemcitabine (1000 mg/m (2) on days 1 and 8 of a 21-day schedule) and carboplatin (AUC 4.5 day 1).
  • Median time to progression was 5.34 months.
  • There was no restriction of renal function under chemotherapy in any single patient.
  • CONCLUSIONS: The chemotherapy combination of gemcitabine and carboplatin is definitely powerful for a first-line-therapy in patients with advanced TCC.
  • Patients with metastatic TCC should be entered onto well designed, randomised clinical trials with the gemcitabine/carboplatin combination to afford a tailored chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Failure, Chronic / complications. Kidney Function Tests. Ureteral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Kidney Pelvis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Prospective Studies. Survival Rate. Ureter / pathology. Urinary Bladder / pathology


9. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol; 2004 Oct;172(4 Pt 1):1271-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
  • The role of adjuvant radiation therapy and chemotherapy is not well defined.
  • We retrospectively reviewed the records of 31 patients who underwent surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy to determine overall outcome as well as impact of concurrent chemotherapy administration.
  • MATERIALS AND METHODS: Between 1970 and 1997, 31 patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (renal pelvis in 13, ureter in 15, and renal pelvis and ureter in 3) were treated with radiotherapy following attempted curative resection.
  • The median radiation dose was 46.9 Gy.
  • Nine patients received methotrexate, cisplatin and vinblastine chemotherapy for 2 to 4 cycles, followed by concurrent cisplatin with radiation.
  • Seven patients (23%) experienced locoregional failure with distant metastases developing in all except 1 within 8 months of locoregional failure diagnosis.
  • Five-year actuarial overall survival, disease specific survival, locoregional control and metastasis-free survival rates were 39%, 52%, 67% and 48%, respectively.
  • On univariate analysis patients had improved 5-year actuarial overall and disease specific survival with the administration of concurrent chemotherapy (27% vs 67%, p = 0.01 and 41% vs 76%, p = 0.06, respectively).
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Pelvis. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Outcome and Process Assessment (Health Care). Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Ureter / pathology. Ureter / surgery


10. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Although laparoscopy is being increasingly used to treat urological malignancies, there is still concern regarding the induction of local recurrence and port site metastasis.
  • We assessed the oncological safety of laparoscopy with emphasis on incidence of local recurrence and port site metastasis, analyzing the risk factors for such events based on a 10-year experience.
  • There were recurrences after nephroureterectomy for transitional cell carcinoma of the ureter in 1 patient, after radical nephrectomy for renal cell carcinoma in 1, growing teratoma after retroperitoneal lymph node dissection in 2, local recurrence of prostate cancer in 3 and after removal of an adrenal metastasis of melanoma in 1.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • CONCLUSIONS: According to our experience the incidence of local recurrence and the risk of port site metastases is low and seems to be mainly related to the aggressiveness of the tumor and immunosuppression status of the patient, respectively rather than to technical aspects of the laparoscopic approach.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Haddock MG, Gunderson LL, Nelson H, Cha SS, Devine RM, Dozois RR, Wolff BG: Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys; 2001 Apr 1;49(5):1267-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Information in the literature regarding salvage treatment for patients with locally recurrent colorectal cancer who have previously been treated with high or moderate dose external beam irradiation (EBRT) is scarce.
  • A retrospective review was therefore performed in our institution to determine disease control, survival, and tolerance in patients treated aggressively with surgical resection and intraoperative electron irradiation (IOERT) +/- additional EBRT and chemotherapy.
  • METHODS AND MATERIALS: From 1981 through 1994, 51 previously irradiated patients with recurrent locally advanced colorectal cancer without evidence of distant metastatic disease were treated at Mayo Clinic Rochester with surgical resection and IOERT +/- additional EBRT.
  • The median IOERT dose was 20 Gy (range, 10--30 Gy).
  • Thirty-seven patients received additional EBRT either pre- or postoperatively with doses ranging from 5 to 50.4 Gy (median 25.2 Gy).
  • Three patients received additional cycles of 5-fluorouracil +/- leucovorin as maintenance chemotherapy.
  • There is a trend toward improved local control in patients who received > or =30 Gy EBRT in addition to IOERT as compared to those who received no EBRT or <30 Gy with 2-yr local control rates of 81% vs. 54%.
  • Distant metastatic disease has developed in 25 patients, and the actuarial rate of distant progression at 2 and 4 years is 56% and 76%, respectively.
  • Peripheral neuropathy was the main IOERT-related toxicity; 16 (32%) patients developed neuropathies (7 mild, 5 moderate, 4 severe).
  • All but one patient with neuropathy or ureter fibrosis received IOERT doses > or =20 Gy.
  • CONCLUSION: Long-term local control can be obtained in a substantial proportion of patients with aggressive combined modality therapy, but long-term survival is poor due to the high rate of distant metastasis.
  • Strategies to improve survival in these poor-risk patients may include the more routine use of conventional systemic chemotherapy or the addition of novel systemic therapies.
  • [MeSH-major] Colonic Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11286833.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Querleu D, Dargent D, Ansquer Y, Leblanc E, Narducci F: Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas. Cancer; 2000 Apr 15;88(8):1883-91
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indication for extended lymph node staging was bulky early stage in 33 patients, International Federation of Gynecology and Obstetrics distal Stage IIB or higher in 14 patients, nonbulky early stage with microscopic positive pelvic lymph nodes in 1 patient, and central recurrence in 5 patients.
  • RESULTS: The procedure failed in two patients.
  • An intraoperative complication occurred in one patient, in whom a lateral injury to a fixed and dilated ureter was managed by stenting.
  • A postoperative complication occurred in another patient, in whom a retroperitoneal hematoma causing ileus and compression of the upper ureter was managed conservatively.
  • All patients but one had external radiation therapy tailored according to the aortic lymph node status.
  • Two patients developed radiation enteritis.
  • CONCLUSIONS: This new technique deserves to be used as a tool to identify lymph node positive patients who require extended-field radiation and/or chemotherapy.
  • [MeSH-major] Lymph Node Excision / methods. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aorta. Endoscopy / methods. Female. Humans. Iliac Artery. Lymphatic Metastasis / diagnosis. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Treatment Outcome


13. Mekki M, Belghith M, Krichène I, Zakhama A, Landolsi A, Chelly S, Nouri A: [Fetal rhabomyomatous nephroblastoma. Report of 2 cases and review of the literature]. Ann Urol (Paris); 2002 Jul;36(4):245-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fetal rhabomyomatous nephroblastoma. Report of 2 cases and review of the literature].
  • The aim of this work is to study the principal clinic, therapeutic and evolutive characteristics of the fetal rhabdomyomatous nephroblastoma through two personal cases and a review of the literature.
  • The diagnosis was confirmed in the two cases by the histologic examination.
  • The radiologic and biologic explorations load, in the two cases, to the diagnosis of left nephroblastoma.
  • After a first chemotherapy that did not induce a reduction of the tumoral volume, a widened left nephrectomy was performed for the two patients.
  • The histologic examination of the two pieces of nephrectomy concluded to a fetal rhabdomyomatous nephroblastoma with existence in the second case of an extension of the lesions to the renal pelvis and ureter in the form of a pseudo-botryoïde tumor.
  • The tumor was classified stage I in the first case and stage II N0 in the second.
  • The treatment was completed by an adapted post operative chemotherapy according to the SIOP 9 protocol.
  • CONCLUSION: The fetal rhabdomyomatous nephroblastoma is a special histologic form of nephroblastoma that is characterized by the paucity of pulmonary metastasis, the absence of response to chemotherapy and the possibility of tumoral extension in the renal pelvis and ureter.
  • [MeSH-major] Kidney Neoplasms. Wilms Tumor
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant. Kidney / pathology. Male. Nephrectomy. Prognosis. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162188.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F: Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol; 2009 Jun;181(6):2482-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients expected to have pT2-4 disease should undergo lymphadenectomy to improve staging and thereby help guide decision making regarding adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / mortality. Kidney Neoplasms / surgery. Lymph Node Excision. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / mortality. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Lymphatic Metastasis. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Jun;181(6):2412-3 [19371898.001]
  • (PMID = 19371878.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Stakia P, Lagos P, Gourgiotis S, Tzilalis VD, Aloizos S, Salemis NS: Large mass affecting retroperitoneal great vessels: a rare presentation of a cancer of unknown primary with diagnostic dilemma and challenged surgical intervention. J Gastrointest Cancer; 2009;40(1-2):55-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Cancers of unknown primary site (CUPs) consist of a clinical entity which accounts for 3-5% of all solid tumor patients.
  • They are metastatic solid tumors whose fundamental characteristic is the absence of identifiable site of the primary tumor.
  • During the operation, a large mass was identified 2 cm below the left renal artery which was displacing and encompassing the great retroperitoneal vessels and the left ureter.
  • A complete resection of the mass was performed while the histological examination revealed a solitary retroperitoneal lymph node categorized as metastatic adenocarcinoma of unknown primary site.
  • Early surgical excision of the metastatic lesion followed by adjuvant combination chemotherapy should be considered for patients with only a single site of malignancy.
  • [MeSH-major] Adenocarcinoma / secondary. Blood Vessels / pathology. Neoplasms, Unknown Primary / pathology. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Incidental Findings. Lymphatic Metastasis / pathology. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1898-904 [15138469.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):840-6 [11857320.001]
  • [Cites] Oncologist. 1997;2(3):142-152 [10388044.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):203-12 [11419028.001]
  • [Cites] Med Clin North Am. 1996 Jan;80(1):153-71 [8569295.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • (PMID = 19513858.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Makino H, Kametaka H, Koyama T, Seike K: [A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2714-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His history included resections of the left kidney and ureter due to a cancer of the left renal pelvis.
  • The diagnosis was gallbladder cancer with infiltration of the liver and mesoduodenal ligament and lymphatic metastasis.
  • But his condition was judged not to be amenable to surgery: the procedure was limited to an exploratory laparotomy.
  • Chemotherapy composed of gemcitabine 1,000 mg/m2 + CDDP 25 mg/m2 (administered for 2 weeks followed by one week of no treatment, repeated for 8 cycles) was initiated on the 16th day of illness.
  • In a phase III trial (the UK ABC-02 trial) conducted by the American Society of Clinical Oncology (ASCO) in 2009, in which gemcitabine + CDDP combination therapy was compared against gemcitabine monotherapy to treat patients with advanced or metastatic biliary tract cancers, the overall duration of survival was significantly prolonged and the mortality risk reduced.
  • After one cycle applied while the patient was in the hospital, no adverse effects of the chemotherapy were found and a subsequent treatment was given on an outpatient basis.
  • No adverse effects attributable to the chemotherapy were noted until 8 cycles were completed.
  • The tumor marker levels were much reduced.
  • The tumor was reduced in size and marked improvement was noted in bile duct stenosis.
  • With a careful observation of the clinical course, the procedure for unresectable gallbladder cancer shown here may be applied on an outpatient basis.
  • It is an effective and safe therapeutic modality, which may become a standard therapeutic procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224689.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Al-Ali MA, Kashmoula DM, Haddad LF: Surgically treated transitional cell carcinomas of the bladder. The role of radical surgery. Saudi Med J; 2002 Jun;23(6):695-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the treatment outcome and differentiate between the individual behavior of the tumor stages that were studied (Ta, T1, and T2a) with special reference to T2a tumors.
  • They were treated surgically with either transurethral of the bladder tumor (N=45) or radical surgery (N=11).
  • Tumors with frequent recurrences or mulifocal or extending to the ureter or vesical outlet were treated with radical surgery.
  • No adjuvant intraveiscal chemotherapy or bacillus calmette-guerin therapy was practiced.
  • RESULTS: All Ta tumors were controlled by transurethral of the bladder tumor treatment.
  • Seventy-five percent of T1 tumors were controlled by transurethral of the bladder treatment and 25% qualified for radical surgery according to our criteria.
  • Sixty percent of T2a tumors were controlled by transurethral of the bladder treatment and 40% warranted radical surgery.
  • All grade 2a lesions of all stages under study were controlled by transurethral of the bladder treatment.
  • No distant metastasis occurred during the observation period, which ranged from 4 months to 12 years (mean 51 months).
  • Seventy-five percent of all patients, 78% of the transurethral of the bladder treatment group and 64% of the radical surgery group are alive and free of disease for 5 years or more.
  • CONCLUSION: Radical surgery is indicated for T1 and T2a bladder carcinomas if they were multifocal, or extending to the ureter or the vesical outlet or frequently recurring within the first year, specially if they were T1 tumors of grade 3 or T2a tumors of grades 2b and 3.
  • [MeSH-minor] Adult. Aged. Cystectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12070550.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


18. Shimamoto K, Tanji N, Ozaw A, Sasaki T, Ikeda T, Iseda T, Yokoyama M: [Intrascrotal rhabdomyosarcoma in adult: a case report]. Nihon Hinyokika Gakkai Zasshi; 2009 May;100(4):545-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With a diagnosis of right intrascrotal tumor, the patient underwent right high orchiectomy.
  • The pathological diagnosis of pleomorphic rhabdomyosarcoma arisen from the right spermatic cord was made.
  • Computed tomography revealed a single metastasis in the para-vena cava lymph node.
  • Systemic chemotherapy with vincristine, actinomycin D, plus cyclophosphamide (VAC therapy), and etoposide plus cisplatin (EP therapy) were made according to Intergroup Rhabdomyosarcoma Study (IRS)-IV Regimen 45.
  • But the chemotherapy was ineffective and a retoroperitoneal lymphadenectomy (RPLND) was therefore performed.
  • After 3 months following RPLND, the tumor relapsed in a pelvic lymph node involved in right ureter and ileocaecal valve.
  • Resection of the tumor with ileocaecum was performed and then intraoperative radiotherapy (15 Gy) against the tumor bed was performed to ensure the curative effects.
  • After his recovery, he received a total of 6 courses of systemic chemotherapy consisting of vincristin, ifosphamide, etoposide (IRS-IV Regimen 47).
  • The patient was rigorously followed up for 42 months after the final chemotherapy, with no tumor recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Genital Neoplasms, Male / therapy. Lymph Node Excision. Orchiectomy. Radiotherapy, Adjuvant. Rhabdomyosarcoma / therapy. Scrotum
  • [MeSH-minor] Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514277.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, Fleisher M, Bajorin DF: Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol; 2009 Feb;20(2):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating tumor cells in patients with urothelial cancer.
  • BACKGROUND: Approximately 50% of patients with metastatic urothelial cancer (UC) respond to chemotherapy and several months of therapy is required to assess for radiographic response.
  • Blood-based biomarkers may identify patients in whom a specific therapy provides clinical benefit, and this study sought to characterize circulating tumor cells (CTCs) in patients with metastatic UC.
  • PATIENTS AND METHODS: Peripheral blood from patients with metastatic UC was evaluated for CTCs using the CellSearch system.
  • We assessed for associations between CTC counts and the number and sites of metastatic disease.
  • RESULTS: CTC evaluations were carried out in 33 patients with metastatic UC.
  • CONCLUSIONS: CTCs, detected by antibody capture technology, are present in 44% of patients with metastatic UC.
  • Higher numbers of CTCs are seen in patients with a greater number of metastatic sites.
  • One-third of patients have five or more CTCs providing a potential early marker to monitor response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836088.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • The common metastasis is in the lung, liver, brain and bone.
  • Oral metastasis is seldom reported.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • The symptoms were alleviated, but the tumor recurred in the oral cavity 2 years later.
  • Repeated radiotherapy for oral metastasis was performed, but the patient died 4 years after the initial nephroureterectomy due to multiple metastases.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


21. Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ: Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology; 2010 Feb;75(2):328-32
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with pT4 stage, lymph node involvement, or distant metastasis were excluded.
  • LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation.
  • On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival.
  • LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 Feb;75(2):332-3 [20152482.001]
  • [CommentIn] Urology. 2010 Feb;75(2):333 [20152483.001]
  • (PMID = 20018349.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zhang M, Tao R, Zhang C, Shen Z: Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies. Urology; 2010 Oct;76(4):902-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
  • OBJECTIVES: To identify the predictive factors for survival and recurrence of patients with muscle-invasive bladder cancer (MIBC) (urothelial carcinoma) after bladder-conserving therapies and to determine the efficacy of partial cystectomy plus chemotherapy and radiotherapy in the treatment of MIBC.
  • Subjects who had stage pT3-4 disease received adjuvant chemotherapy and radiotherapy.
  • RESULTS: At median follow-up of 31.5 months (range 6-66 months), 46% patients experienced superficial local recurrence and 14% developed muscle-invasive local recurrence.
  • By multivariate analysis, the presence of more than 3 tumors (P = .002, RR 2.718, 95% CI 1.455-5.079) and nonpapillary growth patterns (P = .005, RR 4.537, 95% CI 1.573-13.081) were predictive factors for local cancer recurrence; the presence of more than 3 tumors (P = .002, RR 4.109, 95% CI 1.676-10.072), lymphovascular invasion (P = .001, RR 6.098, 95% CI 2.038-18.246), and partial cystectomy plus ureteral reimplantation (PC plus UR) (P = .011, RR 0.129, 95% CI .027-0.627) were significantly associated with 5-year CSS, and PC plus UR promoted survival.
  • CONCLUSIONS: PC plus chemotherapy and radiotherapy is a rational alternative to radical cystectomy for the treatment of MIBC.
  • Lymphovascular invasion and the presence of more than 3 tumors predict poor outcomes in MIBC after bladder-sparing therapy.
  • [MeSH-major] Blood Vessels / pathology. Carcinoma, Transitional Cell / secondary. Lymphatic Metastasis. Neoplasms, Multiple Primary / pathology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Muscle, Smooth / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Proportional Hazards Models. Radiotherapy, Adjuvant. Replantation. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20709377.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Eng MK, Shalhav AL: Laparoscopic nephroureterectomy: long-term outcomes. Curr Opin Urol; 2008 Mar;18(2):157-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rates of bladder, local and distant recurrence are comparable irrespective of the various methods of managing the distal ureter and bladder cuff currently employed.
  • SUMMARY: As the oncologic outcomes after laparoscopic nephroureterectomy continue to mature, a laparoscopic approach for the renal portion of nephroureterectomy is widely accepted as the gold standard in the treatment of organ-confined upper urinary tract transitional cell carcinoma.
  • The roles of laparoscopic nephroureterectomy, lymph node dissection and adjuvant chemotherapy in advanced upper urinary tract transitional cell carcinoma continue to evolve and remain to be defined.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Laparoscopy. Nephrectomy / methods. Ureter / surgery. Urologic Neoplasms / surgery. Urologic Surgical Procedures / methods
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303536.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


24. Morikawa H, Yamada Y, Oda H, Kitahara K, Kanemura M, Komatsu H, Kawagoe S: [A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF)]. Hinyokika Kiyo; 2001 Jul;47(7):485-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal ultrasonography and abdominal computed tomography revealed left renal pelvic tumor.
  • However, these values were elevated again and CT scan revealed a left pulmonary metastasis 3 months after the operation.
  • In spite of chemotherapy, she died of brain metastases 7 months after the operation.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Granulocyte Colony-Stimulating Factor / biosynthesis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting
  • [MeSH-minor] Aged. Female. Humans. Nephrectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11523133.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 7
  •  go-up   go-down


25. Yasuda Y, Tatokoro M, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):758-63
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation].
  • Computed tomography (CT) scan revealed right hydronephrosis and a slightly enhanced invasive tumor in the right lower ureter, providing a diagnosis of ureteral cancer stage cT3NOM0.
  • After three courses of combination chemotherapy consisting of gemcitabine and cisplatin (GC), one tumor completely disappeared and another achieved a partial response.
  • The patient underwent radiofrequency ablation (RFA) for the residual followed by GC chemotherapy.
  • However, eighteen months later, CT scan of the abdomen revealed two metastatic foci in other hepatic lesion.
  • The patient underwent RFA again followed by GC chemotherapy and then all hepatic metastases have not revealed enlargement.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Catheter Ablation. Liver Neoplasms / secondary. Neoplasms, Multiple Primary. Quality of Life. Ureteral Neoplasms / pathology. Ureteral Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174743.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Abe T, Shinohara N, Harabayashi T, Sazawa A, Akino T, Ishikawa S, Kubota K, Matsuno Y, Osawa T, Shibata T, Toyoda Y, Shinno Y, Kamota S, Minami K, Sakashita S, Kumagai A, Takada N, Togashi M, Sano H, Mori T, Nonomura K: Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy. BJU Int; 2010 Apr;105(8):1102-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy.
  • PATIENTS AND METHODS: Among 325 patients undergoing NU with bladder cuff excision for UUT cancer, in this retrospective multi-institutional study we evaluated 113 who developed bladder tumour after NU.
  • Excluding patients with (i) perioperative systemic chemotherapy or radiotherapy for UUT cancer;.
  • (ii) a history of previous or synchronous bladder cancer at the time of NU;.
  • (iii) distant metastasis at the time of NU;.
  • RESULTS: The grade of the first bladder cancer recurrence strongly correlated with that of the UUT tumour (P < 0.001) and the carcinoma in situ (CIS) lesion with the first bladder cancer recurrence correlated with high grade (grade 3) UUT tumour (P < 0.001).
  • In all, 56 of the assessable 70 patients further developed intravesical recurrence at a median interval of 7 months after the first bladder cancer recurrence.
  • CONCLUSIONS: A large proportion of the patients who developed bladder tumour after NU had further intravesical recurrence, which indicated its refractory nature.
  • [MeSH-major] Kidney Neoplasms / surgery. Neoplasms, Second Primary / pathology. Nephrectomy / methods. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL.
  • (PMID = 19725822.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


27. Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH, Wu WJ: Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol; 2008 Mar;15(3):200-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of HIF-1alpha subunit has been reported to be involved in the carcinogenesis, progression and metastasis of many human cancers.
  • METHODS: Ninety-eight cases (mean age = 63.5 +/- 11.7, range = 23-84 years) of renal pelvic or ureter UC were included in the present study.
  • Those who had distant metastasis at diagnosis, other cancer, urolithiasis, incomplete clinical information or had received radiotherapy or chemotherapy before surgery were excluded.
  • Nuclear HIF-1alpha expression were evaluated by immunohistochemistry staining on a paraffin-embedded section of the tumor and non-malignant upper urinary tract specimens and scored by two qualified pathologists.
  • Tumor HIF-1alpha expression score was significantly correlated with tumor T stage (P < 0.001), N stage (P < 0.001) and grade (P = 0.004).
  • Tumor necrosis was associated with high tumor T stage (P < 0.001), N stage (P = 0.002) and grade (P < 0.001).
  • Higher HIF-1alpha score (negative vs 3-5 vs 6-7) was a significant predictor for cancer-specific survival (Cox regression hazard ratio = 2.23, P = 0.004), and tumor recurrence (Cox regression hazard ratio = 1.58, P = 0.036).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304212.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


28. Gakis G, Merseburger AS, Sotlar K, Kuczyk MA, Sievert KD, Stenzl A: Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol; 2009 Apr;16(4):407-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach.
  • We report on the very rare case of a patient with a malignant melanoma in the right ureter initially hospitalized for colic pains.
  • Histomorphological and immunohistochemical examination of the biopsy specimen demonstrated a malignant neoplasia with HMB45, Melan A and S100 positivity establishing the diagnosis of metastatic malignant melanoma.
  • Hence, partial ureterectomy was performed with no further evidence of disease at the time of surgical intervention.
  • Subsequently, multiple metastases in the renal pelvis and ureter led to secondary nephroureterectomy and retroperitoneal lymphadenectomy with complete excision of the ureteral orifice.
  • Secondary metastatic lesions of the urinary bladder wall were completely resected followed by dacarbazine-based chemotherapy and resection of retroperitoneal recurrences.
  • Based on this case as well as on recent published reports, we propose a possible algorithm for the treatment of metastatic melanoma of the upper urinary tract.
  • [MeSH-major] Algorithms. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Ureteral Neoplasms / secondary. Ureteral Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416402.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R: Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol; 2003 May;13(5):943-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to assess the accuracy of MRI in the staging of intra-abdominal tumor seeding of ovarian carcinoma.
  • The MRI protocol included fat-saturated T1-weighted spin-echo (SE) sequences pre- and post i.v. application of gadopentetate dimeglumine.
  • The criteria for tumor manifestation was contrast enhancement of intra-abdominal soft tissue lesions or peritoneum.
  • Laparotomy and histopathology confirmed 251 abdominal tumor locations.
  • Sensitivity was high in lower pelvis locations (73-83%) except for ureter or bladder infiltration (40%).
  • Magnetic resonance imaging based on contrast-enhanced fat-saturated T1 SE sequences improves planning of cytoreduction preceding chemotherapy in advanced primary or relapsed ovarian carcinoma.
  • [MeSH-major] Contrast Media. Magnetic Resonance Imaging. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Radiographic Image Enhancement
  • [MeSH-minor] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / secondary. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / secondary. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / secondary. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Single-Blind Method. Women's Health

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12695813.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


30. McMahan J, Linneman T: A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. Ann Pharmacother; 2009 Sep;43(9):1532-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
  • OBJECTIVE: To report and describe a case of refractory hypercalcemia of malignancy (HCM) associated with metastatic, transitional-cell carcinoma of the left ureter.
  • Computed tomography scan and liver biopsy revealed recurrent transitional-cell carcinoma with extensive liver metastasis.
  • Four mechanisms of HCM have been recognized thus far, with ectopic tumor production of parathyroid hormone-related protein (PTHrP) being the leading cause.
  • Treatment of HCM revolves around 2 principles: treatment of the underlying malignancy along with reduction of the serum calcium level.
  • Evidence-based therapies for management include: intravenous crystalloid fluids with or without loop diuretics, bisphosphonates, calcitonin, gallium nitrate, and corticosteroids.
  • Therapies used for this patient included aggressive hydration, calcitonin, and 3 distinct treatment courses of intravenous bisphosphonates with varying success.
  • These therapies remain viable options based on individual patient factors.
  • To our knowledge, no published guidelines or algorithms exist for choosing between additional modalities in the treatment of refractory HCM.
  • CONCLUSIONS: For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative.
  • The specific mechanism of hypercalcemia should be considered when developing a treatment regimen for patients who have had a suboptimal response to initial therapy with bisphosphonates.
  • Multiple treatment modalities exist for the treatment of hypercalcemia, each with a different mechanism of action.
  • As with the treatment of other disease states, we can use this knowledge to more specifically target the mechanism of the patient's disease.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Hypercalcemia / drug therapy. Ureteral Neoplasms / complications
  • [MeSH-minor] Aged. Algorithms. Bone Density Conservation Agents / therapeutic use. Calcitonin / therapeutic use. Diphosphonates / therapeutic use. Humans. Imidazoles / therapeutic use. Isotonic Solutions / therapeutic use. Male. Neoplasm Metastasis

  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622757.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Isotonic Solutions; 0 / crystalloid solutions; 6XC1PAD3KF / zoledronic acid; 9007-12-9 / Calcitonin; OYY3447OMC / pamidronate
  •  go-up   go-down


31. Reubi JC: In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci; 2000;921:1-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.
  • The evaluation of peptide receptors in man is relevant to identifying the physiological target tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression for diagnostic or therapeutic intervention.
  • VIP/PACAP receptors have been evaluated in normal and diseased human non-neuronal tissues by using in vitro receptor autoradiography with 125I-VIP or 125I-PACAP in tissue sections.
  • As assessed by subtype-selective VIP analogs, VIP receptors of the VPAC1 subtype are found in a wide variety of tissues including liver, breast, kidney, prostate, ureter, bladder, pancreatic ducts, gastrointestinal mucosa, lung, thyroid, adipose, and lymphoid tissues.
  • VIP/PACAP receptors are expressed in the majority of the most frequently occurring human tumors, including breast, prostate, pancreas, lung, colon, stomach, liver, and bladder carcinomas, as well as lymphomas and meningiomas, predominantly as VPAC1 receptors, as do their tissues of origin.
  • Moreover, the receptor expression in tumors is the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analog treatment for tumor growth inhibition.
  • [MeSH-minor] Autoradiography. Epithelium / metabolism. Female. Humans. In Vitro Techniques. Male. Neoplasm Metastasis. Neoplasms / drug therapy. Neoplasms / metabolism. Neoplasms / radiotherapy. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I. Receptors, Vasoactive Intestinal Peptide, Type II. Receptors, Vasoactive Intestinal Polypeptide, Type I. Tissue Distribution


32. Onoda T, Okamura S, Takakura N, Shiozaki S, Ohno S, Higaki K, Ninomiya M, Ikeda T, Kobayashi N: [A case of recurrent gastric cancer successfully treated with TS-1]. Gan To Kagaku Ryoho; 2001 Apr;28(4):539-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1.
  • Subjective symptoms such as difficulty in walking improved after one week and a partial response was obtained after 2 weeks of treatment.
  • At the end of 4 courses we could remove an indwelling pyelocatheter for the ureter stricture.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Lymph Nodes / pathology. Muscle Neoplasms / drug therapy. Muscle Neoplasms / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secretion. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329792.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down






Advertisement